Literature DB >> 20507399

Efficacy and safety of liposome-encapsulated 4-n-butylresorcinol 0.1% cream for the treatment of melasma: a randomized controlled split-face trial.

Sun Young Huh1, Jung-Won Shin, Jung-Im Na, Chang-Hun Huh, Sang-Woong Youn, Kyoung-Chan Park.   

Abstract

Melasma is an acquired pigmentary disorder that most commonly occurs in women of child-bearing age. Melasma is therapeutically challenging, and most commercially available hypopigmenting agents include tyrosinase inhibitors, which regulate the rate-limiting step of melanogenesis. 4-n-Butylresorcinol has received considerable attention as a novel hypopigmenting agent in the last 15 years because it has an inhibitory effect against tyrosinase and tyrosinase-related protein-1. However, the hypopigmenting effect of 4-n-butylresorcinol in human subjects has only been shown in a few studies. Liposome encapsulation is known to improve stabilization and enhance penetration of the product. Therefore, this study was conducted to evaluate the hypopigmenting efficacy and safety of liposome-encapsulated 4-n-butylresorcinol 0.1% cream in patients with melasma. This was a randomized, double-blind, vehicle-controlled and split-face comparison study. Twenty-three patients with a clinical diagnosis of melasma were included. 4-n-Butylresorcinol 0.1% cream or vehicle was applied to each side of the face twice daily for 8 weeks. Clinical and photographic evaluations, Mexameter measurements and assessment of patient satisfaction and side-effects were performed at baseline, 4 and 8 weeks. All subjects completed the study. Mexameter measurements demonstrated that the melanin index of the 4-n-butylresorcinol-treated side showed a significant decrease when compared with the vehicle-treated side after 8 weeks (P = 0.043). No adverse reactions were observed throughout the study. Subjectively, 4-n-butylresorcinol was considered to be efficacious in more than 60% of the patients after 8 weeks of treatment. In conclusion, liposome-encapsulated 4-n-butylresorcinol 0.1% cream was well tolerated and showed significant higher efficacy than vehicle alone for the treatment of melasma.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20507399     DOI: 10.1111/j.1346-8138.2010.00787.x

Source DB:  PubMed          Journal:  J Dermatol        ISSN: 0385-2407            Impact factor:   4.005


  9 in total

Review 1.  Confetti-like Sparing: A Diagnostic Clinical Feature of Melasma.

Authors:  Douglas C Wu; Richard E Fitzpatrick; Mitchel P Goldman
Journal:  J Clin Aesthet Dermatol       Date:  2016-02

2.  Topical hypopigmenting agents for pigmentary disorders and their mechanisms of action.

Authors:  Hyojin Kim; Hye-Ryung Choi; Dong-Seok Kim; Kyoung-Chan Park
Journal:  Ann Dermatol       Date:  2012-02-02       Impact factor: 1.444

Review 3.  Melasma update.

Authors:  Rashmi Sarkar; Pooja Arora; Vijay Kumar Garg; Sidharth Sonthalia; Narendra Gokhale
Journal:  Indian Dermatol Online J       Date:  2014-10

4.  Evidence-based Review, Grade of Recommendation, and Suggested Treatment Recommendations for Melasma.

Authors:  Nilendu Sarma; Sayantani Chakraborty; Shital A Poojary; Sanjay Rathi; Sendhil Kumaran; Balakrishnan Nirmal; Joan Felicita; Rashmi Sarkar; Prashansa Jaiswal; Paschal D'Souza; Nagaraju Donthula; Sumit Sethi; Pallavi Ailawadi; Bebisha Joseph
Journal:  Indian Dermatol Online J       Date:  2017 Nov-Dec

5.  Medical Management of Melasma: A Review with Consensus Recommendations by Indian Pigmentary Expert Group.

Authors:  Rashmi Sarkar; Narendra Gokhale; Kiran Godse; Pallavi Ailawadi; Latika Arya; Nilendu Sarma; R G Torsekar; V K Somani; Pooja Arora; Imran Majid; G Ravichandran; Mohan Singh; Sanjeev Aurangabadkar; Shehnaz Arsiwala; Sidharth Sonthalia; T Salim; Swapnil Shah
Journal:  Indian J Dermatol       Date:  2017 Nov-Dec       Impact factor: 1.494

Review 6.  Skin whitening agents: medicinal chemistry perspective of tyrosinase inhibitors.

Authors:  Thanigaimalai Pillaiyar; Manoj Manickam; Vigneshwaran Namasivayam
Journal:  J Enzyme Inhib Med Chem       Date:  2017-12       Impact factor: 5.051

7.  4-n-Butylresorcinol-Based Linear and Graft Polymethacrylates for Arbutin and Vitamins Delivery by Micellar Systems.

Authors:  Justyna Odrobińska; Łukasz Mielańczyk; Dorota Neugebauer
Journal:  Polymers (Basel)       Date:  2020-02-05       Impact factor: 4.329

Review 8.  Nanocarriers as Active Ingredients Enhancers in the Cosmetic Industry-The European and North America Regulation Challenges.

Authors:  Cristiana Oliveira; Cristina Coelho; José A Teixeira; Pedro Ferreira-Santos; Claudia M Botelho
Journal:  Molecules       Date:  2022-03-03       Impact factor: 4.411

Review 9.  Understanding Melasma-How Can Pharmacology and Cosmetology Procedures and Prevention Help to Achieve Optimal Treatment Results? A Narrative Review.

Authors:  Zuzanna Piętowska; Danuta Nowicka; Jacek C Szepietowski
Journal:  Int J Environ Res Public Health       Date:  2022-09-24       Impact factor: 4.614

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.